Company: AZN
Filing Date: 2025-09-17
Form Type: 6-K
Source: 0001654954-25-010845
Chunk: 3

Company: ASTRAZENECA PLC
Filing Date: 2025-09-17
Form: 6-K
Chunk 3
---
ission in immune-mediated diseases.

#### AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca .

#### Contacts
For details on how to contact the Investor Relations Team, please click here . For Media contact, click here .

#### References
1. Wechsler ME, et al. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med . 2024;390(10):911-921.

2. Fasenra (benralizumab) US prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761070s021lbl.pdf . [Last accessed: September 2025].

3. EMA Fasenra Product Information. Available at: https://www.ema.europa.eu/en/documents/product-information/fasenra-epar-product-information_en.pdf. [Last accessed: September 2025].

4. AstraZeneca news release. Available at: https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-china-for-the-treatment-of-severe-eosinophilic-asthma.html [Last accessed: September 2025]

5. AstraZeneca news release. Available at: https://www.astrazeneca.com/media-centre/press-releases/2018/fasenra-recieves-approval-in-japan-19012018.html

# [Last accessed: September 2025].
6. AstraZeneca Annual Report 2024. Available at: Annual report 2024 . [Last accessed: September 2025].

7. AstraZeneca Data on File. 2025. Fasenra Program Update August 2025. REF-287072.

8. Adeloye D, et al. Global, regional